Opinion
- Home
- Opinion
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Does Paypal’s entry into the BNPL space mean trouble for Afterpay?
- Review
- September 1, 2020
Latest Articles
July 2022 Economic Wrap and the ASX Stocks that Moved
Boris Johnson resigned as the U.K. Prime Minister. Japan’s former Prime Minister Shinzo Abe was assassinated. Italy is in political turmoil with Prime Minister Mario Draghi resigning leading to President Sergio Mattarella dissolving parliament. July 2022 was a remarkable month. US Markets were stronger in the month, with the Dow Jones up +6.7% and S&P
Read MorePublic
Finally time to buy Tech and Discretionary stocks?
Something is in the water. The current market environment is nothing like we have seen before. High prices, high inflation, high interest rates and now the largest world economy slipping into technical recession. But, now is looking like a good time to buy. To understand what direction interest rates are heading, Tim and Mike discussRead MorePublic
Existential childcare crisis: G8 Education appoints discount retail boss as CEO
A secret war is taking place across Australia’s childcare industry and despite their struggles on the battlefield, G8 Education (ASX: GEM) is doubling down by appointing a new CEO who once again, has zero experience in early childhood education. Since the onset of COVID, the pandemic has wreaked havoc on Australia’s childcare industry through a
Read MorePublic
Emerald Financial Research Note Update – Pharmaxis Ltd
The Advisors at Emerald Financial recently released an updated Buy report on Pharmaxis Ltd (ASX: PXS). Key Highlights include: Strong clinical pipeline with endorsement from leading researchers and institutions worldwide Expected preliminary data for Phase 2 trials in myelofibrosis before end of 2022 Phase 2 trial investigating liver cancer to be initiated following successful preclinicalRead MorePublic
Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?
If you read my articles often, you would know that I can become quite laudatory when discussing small cap companies excelling in recreational drug regulation and using once illegal drugs to treat various mental health conditions and illnesses. Ranging from cannabis to psychedelics, and now, MDMA. Most of my articles surrounding this area follow the
Read MorePublic
In the wake of MYOB, is Reckon now one of the most undervalued stocks on the ASX?
At the heart of ANZ’s rumoured takeover of accounting software company MYOB is the customers. The business customers that bring potential cross-selling opportunities into ANZ’s primary services is the underlying motive for the talks because businesses spend a hell of a lot more dough on their banking services than they do their accounting software. So
Read MorePublic